You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Development and Commercialization of a Tau Oligomer Inhibitor for AD/RD
SBC: OLIGOMERIX INC Topic: RPROJECT SUMMARY: This R44 supplement application is focused on the development of a comprehensive publication strategy to meet the company’s long-standing goal of disseminating its findings to the scientific community. The proposed work is designed to create a long term publication plan for the company which will include the writing and publishing of (2) manuscripts during the project term. The ...
SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health -
KAPS Biotech: A novel biomarker to improve prostate cancer diagnosis
SBC: KAPS BIOTECHNOLOGY LLC Topic: 102Abstract Prostate cancer (CaP) is the most common non-skin cancer in men and third most common cause of cancer deaths in men. Black men experience a higher burden of incidence and mortality from CaP compared to White men. The Prostate-Specific Antigen (PSA) test, a commonly used biomarker for early diagnosis and management of CaP, cannot alone accurately predict the presence of CaP, its aggressive ...
STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health -
Developing Nanopieces, a Platform RNAi Delivery Technology for Treatment of Multiple Diseases
SBC: Nanode Therapeutics, Inc. Topic: NCATSSTTR_Developing Nanopieces 7. Project Summary/Abstract The bottleneck of developing new RNAi (RNA Interference) drugs is the lack of highly efficient and non-toxic RNA delivery to non-liver tissues in vivo. It is especially challenging to deliver negatively-charged nucleic acid into avascular, dense, and negatively-charged matrix in hard-to-reach tissues including joint cartilage. NanoDe Therapeut ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
A New Superconducting Detector Technology for Mass Spectrometry of Large Biomolecules
SBC: Steam Instruments, Inc. Topic: 400Project Summary/Abstract The long-term goal of our efforts is to enable identification and mapping of every molecule in a cell. Such information is sought in many life-science disciplines including molecular biology, pathology, proteomics and for the pharmaceutical industry. It is critical information needed to underpin fundamental advances in our understanding of life processes. However, this vis ...
SBIR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Cell-based assay directly monitoring viral polymerase activity for drug discovery.
SBC: LUCERNA INC Topic: NIAIDProject Abstract/Summary Our goal is to develop a new cell-based HTS platform that can be used to improve antiviral drug discovery. Infection by Dengue virus causes ~100 million illnesses annually, with outbreak severity and frequency increasing with time. This is true of all RNA viruses, which includes Zika, Ebola, Influenza, Yellow Fever, and Hepatitis C, to name a few. In addition to the health ...
SBIR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
An innovative platform and smartphone app to deliver tailored interventions and facilitate completed referrals related to substance use.
SBC: Chess Mobile Health, Inc. Topic: NIDAAbstract The goal of this fast-track SBIR proposal is to increase patient adherence to SBIRT-related recommendations given to patients by a primary care provider (PCP). The success of SBIRT (Screening, Brief Intervention, and Referral to Treatment) in the primary care setting has been inconsistent in terms of patients following through on treatment referral recommendations, with averages as low as ...
SBIR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Detection of fetal platelets in maternal blood using platelet RNA biomarkers.
SBC: BLOOD CELL TECHNOLOGIES LLC Topic: NHLBIProgram Director/Principal Investigator (Last, First, Middle): Gnatenko, Dmitri V. ABSTRACT Platelets are small anucleate cells that have a key role in hemostasis, thrombosis, inflammation, wound healing and immune response. They contain a diverse array of mRNAs and microRNAs that can serve as biomarkers of various diseases including cancer. Platelets play important role(s) in pregnancy–associat ...
SBIR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
A Novel Polymeric Valve for Transcatheter Aortic Valve Replacement
SBC: POLYNOVA CARDIOVASCULAR INC Topic: NHLBIProject Summary: A Novel Polymeric Valve for Transcatheter Aortic Valve Replacement Minimally invasive transcatheter aortic valve replacement (TAVR) has emerged as an effective therapy for the unmet clinical need of inoperable patients with severe aortic stenosis (AS). Recent longitudinal follow-up studies of TAVR patients however indicate that this procedure and associated technology may result i ...
STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health -
Multi-gram enzymatic production of complex glycans by flow processes
SBC: ZYMTRONIX CATALYTIC SYSTEMS, INC. Topic: 300Abstract: Zymtronix proposes to significantly improve production efficiency of glycans via new flow processes based on chemoenzymatic catalysis to take significant steps towards broader commercial access. The first glycans of interest are human milk oligosaccharides (HMOs), which have large commercial relevance in infant nutrition, disease prevention and therapeutics. The primary hurdle towards th ...
SBIR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Production and Testing of VLP-based RSV Vaccine
SBC: TECHNOVAX INC Topic: NIAIDPROJECT SUMMARY The goal of this SBIR phase I proposal is to advance the development of a safe and efficacious virus-like particle (VLP) based-respiratory syncytial virus (RSV) vaccine to prevent the disease caused by this pathogen. The respiratory illnesses provoked by RSV in infants, children and the elderly are of global economical and public health impact. A recent worldwide estimate [1,2] ind ...
SBIR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health